
Prenatal Exposure, Maternal Factors Drive Childhood BMI
Childhood obesity remains a major risk factor for chronic health complications throughout life, and identifying modifiable early-life factors may help guide interventions and prevention, wrote Chang Liu, PhD, a psychologist at Washington State University, Pullman, Washington, and colleagues.
'This study allowed us to identify children following unhealthy growth trajectories as early as age 3.5 years and identify the point where BMI starts to show rapid changes such as adiposity rebound, creating crucial opportunities for intervention before obesity becomes established,' Liu said in an interview.
In a study published in JAMA Network Open , the researchers analyzed data from the Environmental Influences on Child Health Outcomes (ECHO) cohort from January 1997 to June 2024. The final study population included 9483 children (approximately half were boys) from 23 longitudinal pediatric cohorts in the United States and Puerto Rico born between 1997 and 2019.
The primary outcome was childhood BMI. The researchers categorized the children into two BMI trajectories, typical and atypical, using a novel model based on BMI shifts over time. Children with a typical trajectory (8477 children; 89.4%) showed linear BMI decreases to 6 years of age, followed by linear increases from age 6 to 9 years. Children with an atypical trajectory (10 children; 6%) showed early stable BMI from age 1 to 3.5 years, followed by rapid linear increases from 3.5 to 9 years.
The researchers assessed prenatal exposures to smoking, alcohol, and stress (depression or anxiety) as well as maternal characteristics of prepregnancy BMI, gestational weight gain, and child characteristics of preterm birth, birth weight, and breastfeeding.
The analysis used a multiphase latent growth mixture model to identify qualitative shifts in BMI during childhood that have not been addressed in previous studies, the researchers noted.
At 9 years of age, the atypical group had a mean BMI of 26.2, higher than the 99th percentile. Prenatal smoking, high prepregnancy BMI, high gestational weight gain, and high birth weight were significantly associated with the atypical trajectory.
The findings were limited by several factors, including the clinical utility of the researchers' multiphase model, which the researchers described as 'more computationally intensive than traditional methods of identifying abnormal childhood growth patterns.' Other limitations included the use of BMI values that may show variations in levels of adiposity based on age and sex, the lack of control for some social determinants of health, and incomplete data on BMI during school age and some perinatal exposures, the researchers wrote.
Implications and Research Gaps
Despite these limitations, the study identified factors that increase the risk for childhood obesity, and addressing these factors could help redirect unhealthy BMI trajectories, the researchers concluded.
'Without intervention, children exhibiting high BMI trajectories during childhood are more likely to develop overweight or obesity as adolescents and adults and are at higher risk for a range of metabolic and cardiovascular diseases throughout their lifetimes,' Liu told Medscape Medical News . Although examination of developmental pathways that lead to unhealthy vs healthy BMIs is crucial to identify modifiable early life factors, 'the challenge has been that most previous research couldn't pinpoint exactly when children's growth patterns start going off track,' Liu said.
Opportunities for clinicians include helping women of reproductive age achieve healthy weight and smoking cessation before pregnancy, supporting appropriate gestational weight gain during pregnancy, and closely monitoring children who show early signs of non-declining BMI patterns, especially those with identified risk factors, Liu said.
Further studies are needed to examine the biological mechanisms linking these early-life factors to different childhood BMI trajectories, Liu told Medscape Medical News . 'Additionally, research is needed to understand how social and environmental factors contribute to the racial and ethnic disparities we observed in growth patterns,' she said. 'Future work should test whether interventions targeting these modifiable factors during critical developmental periods can successfully help children maintain healthier growth trajectories,' Liu added.
Expanding Awareness of Obesity Risk
Early identification of risk for pediatric obesity can be crucial to minimizing disease morbidity and mortality, said Charles Hannum, MD, a general pediatrician at Tufts Medical Center, Boston, in an interview.
The current study not only confirms previously known risks but also adds new information to help pediatricians identify young children who would benefit from a more nuanced approach to growth monitoring and who may also benefit from a more robust prevention strategy for obesity, he said.
The data also show how maternal factors and the pregnancy environment influence child health, said Hannum. 'Lastly, this study is from a large, diverse population group, making the study conclusions more generalizable to the population of the United States,' he said.
Although some of the study findings were known, such as the association between childhood obesity and prenatal smoking, the current study adds the dimension of how that risk connects to the child's growth trend over time, said Hannum.
'The growth trend is often how pediatricians monitor this risk anecdotally,' he said. The associations between BMI trajectory and modifiable risks are not unexpected, but they help support the assumptions clinicians often make about obesity risk and can inform more focused and individually tailored prevention strategies, he noted.
The data can help support both public health initiatives and clinical practice at the individual level, Hannum told Medscape Medical News . For pediatricians, the findings support starting obesity prevention strategies early and monitoring children who have an at-risk BMI trajectory more frequently, he noted. When children do not follow a trajectory of decreased BMI from early to late toddlerhood, even if a BMI is normal, 'we now have evidence that they have an increased risk for developing obesity, and this knowledge may help to prevent some cases of pediatric obesity,' Hannum said.
Add More Variables in Further Research
The current study's limitations include missing and incomplete data and possible challenges when applying the trajectories to broad, diverse populations, given the complex contributors to pediatric obesity, Hannum told Medscape Medical News . More clarity is also needed on when and how to prioritize prevention strategies in the setting of additional obesity risk factors, Hannum added.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBS News
12 minutes ago
- CBS News
Looking to beat the heat in the Twin Cities? Here's a list of cooling centers around the metro
An excessive heat warning is in place across the Twin Cities metro Sunday as feels-like temperatures surpass 100 degrees. WCCO has issued a NEXT Weather Alert for Sunday due to the dangerous heat, as well as the risk for severe storms. For those looking for a place to stay cool, there are options. The following places have cooling centers open across the Twin Cities for free during business hours: For a complete list of cooling centers open in Hennepin County, click here. Minneapolis also has several free pools, beaches and splash pads to help people beat the heat. To see a map of all the cooling centers and beaches in Ramsey County, click here. To stay cool, experts encourage people to limit time in direct sunlight and drink plenty of water. If you're going to be outside in the heat, doctors encourage wearing loose, light clothing and seeking shade when you can. It's recommended that anyone working or exercising in the elements drink at least one cup of water for every 20 minutes. Older adults, young kids and anyone with underlying conditions are at greater risk from extreme heat. In Minnesota, the number of heat-related hospitalizations spikes at a feels-like temperature of only 86 degrees. Cramps, rapid pulse and dizziness are early signs to watch out for when it comes to heat-related illness. Adam Del Rosso and Aki Nace contributed to this report.

Wall Street Journal
44 minutes ago
- Wall Street Journal
Do We Need to Make Coca-Cola Great Again?
Your editorial states that President Trump is pressing Coca-Cola to use cane sugar instead of corn syrup and that Health Secretary Robert F. Kennedy Jr. has said that corn syrup can cause obesity and diabetes ('Trump, Coke and the Sugar Cartel,' Review & Outlook, July 24). Why is Mr. Trump concerned with Coca-Cola? How does he know that Coke is better with cane sugar, when he reportedly drinks 12 cans of Diet Coke each day? Diet Coke contains aspartame, an artificial sweetener, and Mr. Kennedy has repeatedly stated that artificial sweeteners are detrimental to one's health. Is Mr. Trump going to give up Diet Coke? Is he going to press Coca-Cola to change the sweetener in Diet Coke?
Yahoo
an hour ago
- Yahoo
2 Healthcare Stocks That Are Losing to the S&P 500 This Year
Key Points Novo Nordisk and Regeneron have encountered challenges recently. Both companies are significantly trailing the market this year. These healthcare leaders still could perform well in the long run. 10 stocks we like better than Novo Nordisk › Even with all the volatility and the flirting with bear-market territory, the S&P 500 index is well in the green this year, up about 8% since early January. Some stocks haven't been so lucky, though. Novo Nordisk (NYSE: NVO) and Regeneron Pharmaceuticals (NASDAQ: REGN), two leading drugmakers, have underperformed for most of the year, significantly lagging the broader market. These healthcare giants are facing some headwinds, but does that mean investors should steer clear of them? Let's find out. 1. Novo Nordisk Novo Nordisk has been facing several challenges that predate this year. It encountered a clinical setback for what Wall Street thought was a promising weight management candidate. Furthermore, the company's financial results, although strong when compared to its similarly sized peers, were not seen as sufficient because it's held to a higher standard. These challenges have led to a terrible performance this year. Novo Nordisk's shares are down by 18% year to date, significantly lagging the S&P 500. However, the stock might be a steal right now. The company has made several moves that should allow it to recover. Novo Nordisk's pipeline, especially in diabetes and weight management, remains one of the strongest in the industry. It recently initiated a phase 3 study for amycretin -- its next-generation GLP-1 medicine -- in both subcutaneous and oral formulations. It requested regulatory approval in the U.S. for an oral version of semaglutide, its well-known medicine marketed as Wegovy for weight loss and as Ozempic for diabetes management. Novo Nordisk has also penned several licensing deals that have expanded its pipeline in weight management. The company should launch at least one new medicine in its core therapeutic area within the next few years. Financial results should remain strong as Ozempic and Wegovy continue driving solid revenue growth. Considering the stock's sell-off over the past years, shares now look more than reasonably valued relative to Novo Nordisk's growth potential. Their forward price-to-earnings ratio of 16.9 is in line with the healthcare industry's average of 16.5 as of this writing. However, Novo Nordisk typically grows its revenue and earnings faster than its peers. That makes its stock attractive at current levels, based on its growth potential. 2. Regeneron Pharmaceuticals Regeneron is facing biosimilar competition for Eylea, a medicine for wet age-related macular degeneration that was once one of its biggest growth drivers. Sales of the medicine have dropped, dragging total revenue down with them. That's the most important reason why Regeneron's shares are down by 19% since the year started. However, the stock is still attractive. The biotech might go through a period of its top line declining, but it can still recover. Here are three reasons why. First, the company's newer, higher-dose (HD) formulation of Eylea is taking market share away from its previous version. HD Eylea is performing well and will grow even faster once it earns some label expansions. Second, Regeneron has a deep pipeline that's expected to yield new brand approvals. Earlier this month, it earned the green light for Lynozyfic, a cancer medicine, in the U.S. One of its more promising candidates is a gene therapy for one type of genetic deafness, which is showing incredible potential in clinical trials. Regeneron should move beyond Eylea thanks to newer approvals. Third, the company's most important product, Dupixent, an eczema treatment, is performing exceptionally well. The medicine has earned important label expansions in recent years, including in treating chronic obstructive pulmonary disease (COPD) and a rare skin condition called bullous pemphigoid. Dupixent will maintain its upward growth trajectory for a while. Here's one more reason to invest in Regeneron: The company is committed to returning capital to shareholders. It recently initiated a dividend and has a robust share-buyback program in place. The stock might be moving in the wrong direction right now, but those willing to hold onto it for five years or more could see superior returns over the long run. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Prosper Junior Bakiny has positions in Novo Nordisk. The Motley Fool has positions in and recommends Regeneron Pharmaceuticals. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Healthcare Stocks That Are Losing to the S&P 500 This Year was originally published by The Motley Fool Connectez-vous pour accéder à votre portefeuille